Cervarix | FDA - U.S. Food and Drug Administration
Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human...
希瑞适 | 葛兰素史克公司网站 - GSK China
双价人乳头瘤病毒吸附疫苗 （商品名：希瑞适），适用于9~45岁女性，用于预防因高危型人乳头瘤病毒（HPV）16、18型所致疾病。 希瑞适肌肉注射，免疫程序为3剂，于0、1和6月分别接种1剂次，每剂0.5ml。 具体信息详见希瑞适产品说明书。 公示文件. 该网站面向查询有关 中国业务信息的访客。 您可通过点击"选择市场”来访问其他业务市场的网站。 © 2001-2024葛兰素史克集团版权所有。 商标归葛兰素史克集团所有或获授权使用。 北京市朝阳区东四环中路 号楼 层. （京）
Cervarix 保蓓 | GSK 台灣
產品英文名稱：Cervarix; 產品主成分：Human Papillomavirus Type 16 L1 Protein, Human Papillomavirus Type 18 L1 Protein Cervarix 保蓓完整仿單下載PDF - 1,529KB. Cervarix 及保蓓為葛蘭素史克集團所有或經授權的商標
Cervarix - Wikipedia
Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV). Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases. [6] These types also cause most …
CERVARIX is a vaccine indicated in females from 9 to 45 years of age for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) by protecting against the following precancerous or dysplastic lesions caused by oncogenic Human Papillomavirus (HPV), types 16
CERVARIXTM is indicated from the age of 9 years for the prevention of persistent infection, premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical, vulvar, vaginal and anal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV) (see Warnings and Precautions and Pharmacody...
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Cervarix | GSK AU
Download Cervarix CMI (PDF-61.0KB) Product Information. The Product Information is intended to assist healthcare professionals make decisions about treatment options and provide advice on the appropriate use of a medicine to patients. This information only applies to GSK products available in Australia. Download Cervarix PI (PDF-476KB)
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
2017年10月6日 · GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Cervarix® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (...
Cervarix — Wikipédia
Le Cervarix (GlaxoSmithKline 2007) est un vaccin contre les génotypes 16 et 18 du papillomavirus humain (HPV) responsables de 70 % des cas de cancer du col de l'utérus [1].